Petros Pharmaceuticals, Inc.
PTPI
$0.0579
$0.00397.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.20% | -42.41% | 6.96% | -22.36% | -2.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.20% | -42.41% | 6.96% | -22.36% | -2.83% |
| Cost of Revenue | -25.66% | -53.02% | -45.01% | -40.35% | -28.75% |
| Gross Profit | -6.96% | -37.02% | 78.60% | -10.77% | 13.20% |
| SG&A Expenses | -5.53% | 9.38% | 4.27% | -5.74% | -24.14% |
| Depreciation & Amortization | -13.76% | -12.34% | -25.80% | -34.76% | -41.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.10% | 4.76% | -3.44% | -6.49% | -24.05% |
| Operating Income | 4.33% | -38.30% | 6.29% | -0.73% | 32.08% |
| Income Before Tax | -75.41% | 62.82% | 67.90% | 57.92% | 59.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.41% | 62.79% | 67.90% | 57.92% | 59.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.41% | 62.79% | 67.90% | 57.92% | 59.26% |
| EBIT | 4.33% | -38.30% | 6.29% | -0.73% | 32.08% |
| EBITDA | 0.19% | -65.05% | -1.81% | -21.24% | 27.01% |
| EPS Basic | 42.21% | 37.69% | 38.38% | 28.30% | 34.59% |
| Normalized Basic EPS | 64.06% | 89.48% | 63.37% | 44.84% | 51.12% |
| EPS Diluted | 42.21% | 37.69% | 38.38% | 28.30% | 34.59% |
| Normalized Diluted EPS | 64.06% | 89.48% | 63.37% | 44.84% | 51.12% |
| Average Basic Shares Outstanding | 268.61% | 189.87% | 99.31% | 36.99% | 5.11% |
| Average Diluted Shares Outstanding | 268.61% | 189.87% | 99.31% | 36.99% | 5.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |